Reuters logo
10 months ago
BRIEF-Transgene announces collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the combination of TG4001 with Avelumab
October 11, 2016 / 4:11 PM / 10 months ago

BRIEF-Transgene announces collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the combination of TG4001 with Avelumab

Oct 11 (Reuters) - Transgene

* Transgene announces collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate the combination of TG4001 with Avelumab in HPV-positive head & neck cancer in a phase 1/2 study

* Transgene- this is an exclusive agreement between parties to study combination of these two classes of investigational agents in HPV-positive HNSCC

* Transgene- phase I trial is expected to begin in France, with first patient expected to be recruited in H1 2017 Source text :

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below